Second-Line Oxaliplatin and Irinotecan Versus Irinotecan Alone for Gemcitabine and S-1 Refractory Pancreatic Cancer

Inclusion Criteria: * Patients with histologically confirmed advanced pancreatic cancer who had experienced progression during first-line gemcitabine and S-1 were eligible for enrollment on this open-label, randomized study. * Additional inclusion criteria were age 18 years or older * Measurable reference cancer site(s) confirmed with computed tomography (CT) or magnetic resonance imaging (MRI) * Karnofsky performance status (KPS) of at least 70% * -Adequate renal function, adequate hepatic function, adequate bone marrow function Exclusion Criteria: * The presence of any severe concomitant disease that could interrupt the planned treatment; intractable pain * Hypersensitivity to study drugs * Serious cardiovascular disease (eg, unstable coronary artery disease or myocardial infarction within 4 weeks of study start) * National Cancer Institute CommonToxicity Criteria grade 3 or 4 sensory or motor neuropathy * Prior or concurrent malignancy (other than pancreatic cancer) * Female, pregnancy or breastfeeding.